Use of topical minoxidil therapy for androgenetic alopecia in women.
BACKGROUND
Androgenetic alopecia is the most common cause of hair loss in men and women. Androgenetic alopecia in women begins as a diffuse and progressive thinning of the frontoparietal area of the scalp. In women, hair loss at any age is socially unacceptable and may be the basis of psychiatric illness.


METHODS
A 32-week, double-blind, placebo-controlled trial was conducted in 10 European centers to assess the efficacy and safety of 2% topical minoxidil solution for the treatment of androgenetic alopecia in women. Two hundred ninety-four of the 346 women enrolled (85%) completed the 32-week trial. Photographic and computer imaging techniques were used at each visit to determine objectively the number of nonvellus hairs present in a 1-cm2 area selected as the target evaluation site.


RESULTS
In the 2% minoxidil group, the mean increase in nonvellus hair count was 33 hairs, which was significantly greater than that of 19 hairs in the placebo group (P = 0.0001). The investigators observed that 44% of the patients in the 2% minoxidil group achieved new hair growth compared with 29% in the placebo group. When asked to evaluate their own hair growth, 55% of the women in the 2% minoxidil group compared to 41% of the women in the placebo group believed that they had achieved new hair growth. No clinically significant changes in vital signs were observed during the study and no serious or unexpected medical events were reported.


CONCLUSIONS
Topical minoxidil solution was significantly more effective than placebo in the treatment of androgenetic alopecia in women.
Jacobs
J P
JP
Dermatology Division, Upjohn Laboratories, Kalamazoo, Michigan.
Szpunar
C A
CA
Warner
M L
ML
D000279:Administration, Cutaneous; D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000505:Alopecia / Q000188:drug therapy* / Q000473:pathology; D003877:Dermatitis, Contact / Q000209:etiology; D004311:Double-Blind Method; D004361:Drug Tolerance; D005260:Female; D006197:Hair / Q000187:drug effects / Q000254:growth & development / Q000473:pathology; D006801:Humans; D008875:Middle Aged; D008914:Minoxidil / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010781:Photography; D010919:Placebos; D012449:Safety; D012536:Scalp Dermatoses / Q000139:chemically induced; D013997:Time Factors
D010919:Placebos; D008914:Minoxidil